This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bachmann, S. P. Articles by López-Ribot, J. L. Search for Related Content PubMed PubMed Citation Articles by Bachmann, S. P. Articles by López-Ribot, J. L.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, June 2002, p. 2228-2230, Vol. 40, No. 6
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.6.2228-2230.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of Caspofungin (MK-0991) against Candida albicans Clinical Isolates Displaying Different Mechanisms of Azole Resistance

Department of Medicine, Division of Infectious Diseases, University of Texas Health Science Center at San Antonio, South Texas Centers for Biology in Medicine, San Antonio, Texas 78245

Received 26 December 2001/ Returned for modification 7 March 2002/ Accepted 17 March 2002

Caspofungin inhibits the synthesis of 1,3-ß-D-glucan, a key step in fungal cell wall biosynthesis. Here we report on its potent in vitro activity (MIC at which 90% of the isolates tested are inhibited = 1 µg per ml of RPMI medium) against 32 Candida albicans fluconazole-susceptible and -resistant clinical isolates irrespective of the underlying resistance mechanism (alterations in ERG11 and/or upregulation of MDR and CDR genes encoding efflux pumps) and provide further evidence that caspofungin is not a substrate for multidrug transporters.

This article has been cited by other articles:

• Pfaller, M. A., Diekema, D. J., Ostrosky-Zeichner, L., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Ghannoum, M. A., Knapp, C. C., Sheehan, D. J., Walsh, T. J. (2008). Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints. J. Clin. Microbiol. 46: 2620-2629 [Abstract] [Full Text]  
• Cowen, L. E., Steinbach, W. J. (2008). Stress, Drugs, and Evolution: the Role of Cellular Signaling in Fungal Drug Resistance. Eukaryot Cell 7: 747-764 [Full Text]  
• Pfaller, M. A., Diekema, D. J. (2007). Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. Clin. Microbiol. Rev. 20: 133-163 [Abstract] [Full Text]  
• Balashov, S. V., Park, S., Perlin, D. S. (2006). Assessing Resistance to the Echinocandin Antifungal Drug Caspofungin in Candida albicans by Profiling Mutations in FKS1.. Antimicrob. Agents Chemother. 50: 2058-2063 [Abstract] [Full Text]  
• Niimi, K., Maki, K., Ikeda, F., Holmes, A. R., Lamping, E., Niimi, M., Monk, B. C., Cannon, R. D. (2006). Overexpression of Candida albicans CDR1, CDR2, or MDR1 Does Not Produce Significant Changes in Echinocandin Susceptibility.. Antimicrob. Agents Chemother. 50: 1148-1155 [Abstract] [Full Text]  
• Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., Flattery, A., Gill, C., Chrebet, G., Parent, S. A., Kurtz, M., Teppler, H., Douglas, C. M., Perlin, D. S. (2005). Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates. Antimicrob. Agents Chemother. 49: 3264-3273 [Abstract] [Full Text]  
• Mitchell, M., Hudspeth, M., Wright, A. (2005). Flow Cytometry Susceptibility Testing for the Antifungal Caspofungin. J. Clin. Microbiol. 43: 2586-2589 [Abstract] [Full Text]  
• De Logu, A., Saddi, M., Cardia, M. C., Borgna, R., Sanna, C., Saddi, B., Maccioni, E. (2005). In vitro activity of 2-cyclohexylidenhydrazo-4-phenyl-thiazole compared with those of amphotericin B and fluconazole against clinical isolates of Candida spp. and fluconazole-resistant Candida albicans. J Antimicrob Chemother 55: 692-698 [Abstract] [Full Text]  
• Moudgal, V., Little, T., Boikov, D., Vazquez, J. A. (2005). Multiechinocandin- and Multiazole-Resistant Candida parapsilosis Isolates Serially Obtained during Therapy for Prosthetic Valve Endocarditis. Antimicrob. Agents Chemother. 49: 767-769 [Abstract] [Full Text]  
• Coste, A. T., Karababa, M., Ischer, F., Bille, J., Sanglard, D. (2004). TAC1, Transcriptional Activator of CDR Genes, Is a New Transcription Factor Involved in the Regulation of Candida albicans ABC Transporters CDR1 and CDR2. Eukaryot Cell 3: 1639-1652 [Abstract] [Full Text]  
• Barchiesi, F., Spreghini, E., Baldassarri, I., Marigliano, A., Arzeni, D., Giannini, D., Scalise, G. (2004). Sequential Therapy with Caspofungin and Fluconazole for Candida albicans Infection. Antimicrob. Agents Chemother. 48: 4056-4058 [Abstract] [Full Text]  
• Carver, P. L (2004). Micafungin. The Annals of Pharmacotherapy 38: 1707-1721 [Abstract] [Full Text]  
• Bachmann, S. P., VandeWalle, K., Ramage, G., Patterson, T. F., Wickes, B. L., Graybill, J. R., Lopez-Ribot, J. L. (2002). In Vitro Activity of Caspofungin against Candida albicans Biofilms. Antimicrob. Agents Chemother. 46: 3591-3596 [Abstract] [Full Text]